Categories: News

Impel Pharmaceuticals to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) — Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced it will host a live webcast on Monday, May 16, 2022, at 8:30 a.m. ET to report its first quarter 2022 financial results and provide a business update.

The conference call may be accessed by dialling 877-295-2648 (domestic) or 470-495-9487 (international) and referring to conference ID 2468863. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the webcast and accompanying slides will be available on the Impel Pharmaceuticals website following the event.

About Impel Pharmaceuticals Inc.
Impel Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. In addition to Trudhesa™ (dihydroergotamine mesylate) nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

For additional information about Impel, please visit www.ImpelPharma.com

Contact:

Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 201-723-5805
Email: mweible@elixirhealthpr.com

Investor Relations
Christina Tartaglia
Stern Investor Relations
Phone: 212-362-1200
Email: christina.tartaglia@sternir.com

Staff

Recent Posts

West Island Brands Acquires Contract to Supply Bio Products Internationally

Toronto, Ontario--(Newsfile Corp. - March 18, 2024) - West Island Brands Inc. (CSE: WIB) (FSE:…

1 hour ago

NextGen Healthcare Chosen by United Medical Centers to Support Integrated Care Delivery in Communities at United States-Mexico Border

Growing Need for Integration Led FQHC to Select NextGen HealthcareREMOTE-FIRST COMPANY/EAGLE PASS, Texas--(BUSINESS WIRE)--#NextGenHealthcare--Driven by…

2 hours ago

The Assistance Fund Opens New Program for Heart Failure

Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Heart FailureORLANDO,…

2 hours ago

US Med-Equip Earns CIO 100 Award for IT Innovation With New AI Solution Helping Clinicians Secure Medical Equipment on Demand

Life-Saving Equipment Delivered to Patients in Record Time, Lower Cost at Hospitals Using Award-Winning GoUSME…

2 hours ago

Zeto Successfully Completes SOC 2 Type II Audit for Its Cloud Platform, Demonstrating Commitment to Data Security

SANTA CLARA, CA / ACCESSWIRE / March 18, 2024 / Zeto, Inc., a commercial-stage medical…

2 hours ago